Cyclacel files Support and Counterclaims to Celgene’s declaratory judgment gripe
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), a biopharmaceutical corporation developing spoken therapies that butt the different phases of cubicle course repress after the treatment of cancer and other weighty disorders, today announced that it filed its Fulfil and Counterclaims to the declaratory judgment kick filed near Celgene Corporation. Cyclacel has filed counterclaims charging Celgene with non-compliance of each of four Cyclacel-owned patents and seeks damages in favour of Celgene’s non-compliance as ok as injunctive relief. The four patents in a little while concern the practise and delivery of Celgene’s ISTODAX® (romidepsin in favour of injection) consequence.
The declaratory judgment squawk seeks to procure the four Cyclacel patents, which requisition the make use of of romidepsin in behalf of injection in T-cell lymphomas, declared erroneous and not infringed close to Celgene’s products.
The four Cyclacel patents which are the undergo of this exertion do not suggest Cyclacel’s clinical condition candidates or its commercial products.
SOURCE Cyclacel Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
